Purpose. The primary objective of this article is to continue the discussion of the pharmacology, phar macokinetics, clinical use, and adverse effects of the currently approved adenosine analogues, focusing on pentostatin. This is part two of a three part series.
Data Sources. We reviewed the literature through a MEDLINE search from 1986 to 1996. Rele vant articles cited in the literature obtained by MED LINE searching also were considered. We searched the following terms: fludarabine, cladribine, pentosta tin, apoptosis, and adenosine analogues. The search was restricted to the English language.
Data Extraction. We have reviewed the current literature in regard to the chemistry, mechanisms of action and pharmacology, pharmacokinetics, clinical use, adverse effects, drug interactions, indications, formulation, dosage, administration, and pharmaceu tical issues of the currently approved adenosoine analogues, focusing on pentostatin.
Data Synthesis. The adenosine analogues are structurally similar agents used in the management of hematological malignancies. Pentostatin and cladrib ine are both active agents in the treatment of hairy cell leukemia. There are no comparative clinical trials between the agents, and we have provided compari sons based on pharmacology, clinical experience, adverse effects, and cost.
Woo Pwk, Dion HW, Lange SM, et al. A novel adenosine and Ara-A inhibitor, (R)-3(2-deoxy-β-D-erythopentofuranosyl)-3,6,7,8, tetra-hydro-imidazole (4-5d)(1-3)diazepin8-ol. J Heterocycl Chem.1974; 11:641-643.
2.
Montgomery JH , Thomas HJ, Zell EL, et al. Study on the inhibition of adenosine deaminase. J Med Chem.1985;28:1751-1753.
3.
Schramm VL, Baker DCSpontaneous epimerization of S-deoxycoformycin and interaction of R-deoxycoformycin, S-deoxycoformycin, and 8-ketodeoxycoformycin with adenosine deaminase. Biocbemistry. 1985;24:6641-6649.
4.
Willey JS, Smith CL, Jameson GPTransport of 2'-deoxycoformycin in human leukemia and lymphoma cells. Biochem Pharmacol.1991;42:708-710.
Tattersal Mhn , Ganeshaguru K., Hoffbrand AVThe effect of external deoxynucleosides on deoxyribonucleoside triphosphate concentration in human lymphocytes. Biocbem PbarinacoL1975 ;24:1495-1498.
7.
Ullman B., Gudas LJ, Cohen A., et al. Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease. Cell.1978; 14:365-375.
8.
Ho AD, Ganeshaguru K., Knauf WU, et al. Clinical response to deoxycoformycin in chronic lymphoid neoplasms and biochemical changes in circulating malignant cells in vivo. Blood.1988;72:1884-1890.
9.
Johnstone AP , Williams GTRole of DNA breaks and ADP-ribosyl transferase activity in eukaryotic differentiation demonstrated in human lymphocytes. Nature. 1982;300:368-370.
10.
Cohen A., Barankiewicz J., Lederman HM, et al. Purine and pyrimidine metabolism in human T lymphocytes. Regulation of deoxyribonucleotide metabolism. J Biol Cbem.1983;258:12334-12340.
11.
Johnston JB , Lee K., Verburb L., et al. Induction of apoptosis in CD4+ prolymphocytic leukemia by deoxyadenosine and 2'-deoxycoformycin. Leuk Res . 1992;16:781-788.
12.
Major PP, Agarwal RP, Kufe DWClinical pharmacology of 2-deoxycoformycin. Blood.1981a;58:91-96.
13.
Grever MR, Staubus AE, Balcerzak SP, et al. Clinical pharmacokinetics of 2-deoxycoformycin in renal impairment . Proc Am Soc Clin Oncol.1993;12:361.
14.
Venner PM, Glazer RI, Blatt J., et al. Levels of 2-deoxycoformycin and deoxyadenosine in patients with acute lymphoblastic leukemia. Cancer Res.1981;41:4508-4511.
15.
Brogden RN, Sorkin EMPentostatin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in lymphoproliferative disorders. Drugs.1993;46:652- 677.
16.
Malspeis L. , Weinrib AB, Straubus AE, et al. Clinical pharmacokinetics of 2-deoxycoformycin . Cancer Treat Symp.1984;2:7-15.
17.
Smyth JF, Paine RM, Jackman AL, et al. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin. Cancer Chemother Pharmacol.1980;5:93-101.
18.
Grever MR, Slaw Mfe, Jacob WF, et al. The biochemical and clinical consequences of pentostatin in refractory lymphoproliferative malignancy. Blood.1981;57:406-417.
19.
Poplack DG, Sallen SE, Rever G., et al. Phase 1 study of 2'-deoxycoformycin in acute lymphoblastic leukemias . Cancer Res.1981;41:3435-3346.
20.
Major PP, Agarwal RP, Kufe DWClinical pharmacology of deoxycoformycin. Blood.1981;58:91-96.
21.
Tobinai K., Shimoyama M., Inoue S., et al. Phase I study of YK-176 (2'-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. The DCF Study Group. Jpn J Clin Oncol.1992;22:164-171.
22.
Smyth JF, Prentice HG, Proctor S., et al. Deoxycoformycin in the treatment of leukemias and lymphomas . Ann N YAcad Sci.1985;451:123-128.
23.
Grever MR, Leiby JM, Kraut EH, et al. Low dose deoxycoformycin in lymphoid malignancy. J Clin Oncol.1985;3:1196-1201.
24.
Dillman RO, Mick R., McIntyre ORPentostatin in chronic lymphocytic leukemia: a phase 2 trial of the Cancer and Leukemia Group B. J Clin Oncol.1989; 7:433- 438.
25.
Ho AD, Thaler J., Stryckmans P., et al. Pentostatin in refractory chronic lymphocytic leukemia: a phase 2 trial by the European Organization for Research and Treatment of Cancer . J Natl Cancer Inst.1990;82: 1416-1420.
26.
Deardon C., Catovsky D.Deoxycoformycin in the treatment of mature B-cell malignancies. Br J Cancer.1990;62:4-5.
27.
Saven A., Piro LDTreatment of hairy cell leukemia. Blood.1992 ;79(5):1111-1120.
28.
Bouroncle BA , Grever MR, Kraught EHTreatment of hairy cell leukemia. The Ohio State experience with deoxycoformycin. Leukemia. 1987 ;4:350-354.
29.
Ho AD, Thaiser J., Mandelli F., et al. Response to pentostatin in hairy cell leukemia refractory to interferon-alpha. J Clin Oncol.1989;7:1533-1538.
30.
Kraut EH, Bouroncle BA, Grever MR, et al. Pentostatin in the treatment of advanced hairy cell leukemia . J Clin Oncol.1989;7:168-172.
31.
Johnston JB , Eisenhauer E., Corbett Wen, et al. Efficacy of 2'-deoxycoformycin in hairy cell leukemia: a study of the National Cancer Institute Canada Clinical Working Trials Group. J Natl Cancer Inst.1988;80:765-766.
32.
Spiers Asd, Moore D., Cassileth PA, et al. Remissions in hairy cell leukemia with pentostatin (2'-deoxycoformycin) . N Engl J Med.1987;316:825-831.
33.
Blick M., Lepe-Zuniga JL, Doig R., et al. Durable complete remissions after 2'-deoxycoformycin treatment in patients with hairy cell leukemia resistant to interferon alpha. Am J Hematol. 1990;33:205-209.
34.
Cassileth PA , Cheuvant B., Spiers Asd, et al. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol.1991 ;9:243-246.
35.
Grever M., Kopecky K., Foucar KM, et al. Randomized comparison of pentostatin vs interferon-a 2a in previously untreated patients with hairy cell leukemia. J Clin Oncol.1995;13:974-982.
36.
Martin A., Nerenstone S., Urba WJ, et al. Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study. J Clin Oncol.1990;8:721-730.
37.
Haberman TM , Anderson JW, Cassileth PA, et al. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukemia . Br J Haematol. 1992;80:466- 471.
38.
Monfardini S., Sorio R., Cavalli F., et al. Pentostatin (2'-deoxycorformycin, dCf) in patients with low-grade (B-T-cell) and intermediate and high grade (T-cell) malignant lymphomas a phase II study of the EORTC Early Clinical Trials Group. Oncology. 1996; 53:163-168.
39.
Duggan DA, Anderson JR, Dillman R., et al. 2'deoxycoformycin (pentostatin) for refractory non-Hodgkin's lymphoma: a CALGB phase II study. Med Pediatr Oncol.1990;18:203-209.
40.
Cummings FJ, Kim K., Neiman RS, et al. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol.1991;9:565-571.
41.
Mercieca J., Matutes E., Deardon C., MacLennan, Catovsky D.The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol.1994; 12:2588-2593.
42.
Grever MR, Bisaccia E., Scarborough DA, et al. An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood.1983; 61:279-282.
43.
Dang-Vu AP, Olsen EA, Vollman RT, et al. Treatment of T-cell lymphoma with 2-deoxycofonnycin. J Am Acad Dermatol.1988;19:692- 698.
44.
Foss FM, Ihde DC, Breneman DL, et al. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa 2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol.1992;10: 1907-1913.
45.
Venner P., Eisenhauer EA, Wierzbicki R., et al. Phase II study of 2'-deoxycoformycin in patients with renal cell carcinoma. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs.1991;9:273-275.
46.
Grever MR, Brager P., Metz E.A phase II investigation of pentostatin in metastatic malignant melanoma. Invest New Drugs.1992;10:345-346.
47.
Grever MR, Crowley J., Salmon S., et al. Phase II investigation of pentostatin in multiple myeloma: a Southwest Oncology Group study. J Natl Cancer Inst.1990;22:1778-1779.
48.
Miser JS, Roloff J., Blatt J., et al. Lack of significant activity of 2'-deoxycoformycin alone or in combination with adenine arabinoside in relapsed childhood acute llymphoblastic leukemia: a randomized phase II trial from the Childrens Cancer Study Group . Am J Clin Oncol.1992;15:490-493.
49.
Kraut EH, Neff JC, Bouroncle BA, et al. Immunosuppressive effects of pentostatin. J Clin Oncol.1990; 8:848-855.
50.
Cheson BD. Infectious and immunosuppressive complications of purine analogue therapy.
51.
O'Dwyer PJ, Spiers Asd, Maroni S., et al. Association of severe and fatal infections and treatment with pentostatin. Cancer Treat Rep.1986;70:117-120.
52.
Speirs Asd.The role of pentostatin (2'-deoxycoformycin) in the management of lymphoproliferative malignancies. Blood Rev.1987;1:106-110.
53.
Phillis JW, Edstrom JPEffects of adenosine analogs on rat cerebral cortical neurons. Life Sci.1976; 19: 1041-1054.
54.
Phillis JW, Kostopoulos JK, Edstrom JP, et al. Role of adenosine and adenine nucleotides in central nervous function. In: Baer HP, Drummond GI, eds. Physiological and regulatory functions of adenosine and adenine nucleotides. New York : Raven, 1979:343-359.
55.
Major PP, Agarwal RP, Kufe DWDeoxycoformycin neurological toxicity. Cancer Chemother Pharmacol.1981;5:193-196.
56.
Major PP, Agarwal RP, Kufe DWClinical pharmacology of deoxycoformycin. Blood.1981;58:91-96.
57.
Cheson BD, Vena DA, Foss FM, Sorensen JMNeurotoxicity of purine analogs: a review. J Clin Oncol.1994;12:2216-2228.
58.
Grever M., Kopecky K., Head D., et al. A randomized comparison of deoxycoformycin (DCF) versus alpha-2a interferon (IFN) in previously untreated patients with hairy cell leukemia (HCL): an NCI sponsored intergroup study (SWOG, ECOG, CALGB, NCIC, CTG). Proc Am Soc Clin Oncol.1992;11:868.
59.
O'Dwyer PJ, Wagner B., Leyland-Jones B., et al. 2'-deoxycoformycin (pentostatin) for lymphoid malignancies: rational development of an active new drug. Ann Intern Med.1988;108:733-743.
60.
Prentice HG , Russell NH, Lee L., et al. Therapeutic selectivity of and prediction of response 2'-deoxycoformycin in acute leukemia. Lancet. 1981;2: 1250-1254.
61.
Karnofsky JR , Baron JM, Roth DG, et al. Treatment of lymphoid malignancies with 2-deoxycoformycin: a pilot study. Am J Clin Oncol.1982;5:179-183.
62.
Grever MR, Siaw Mfe, Jacob WF et al. The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy. Blood.1981;57:406-417.
63.
Bryd JC, Hutler AA, Weiss RB, et al. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with fludarabine-associated hemolytic anemia. Ann Oncol.
64.
Sakai C., Takagi T., Wakatsuki S., Matsuzaki O.Hemolytic uremia syndrome due to deoxycorformycin: a report of the second case. Intern Med.1995 ;34:593-596.
65.
Lindley CM, Bernard SA, Robertson JDVomiting associated with pentostatin and pentostatin plus interferon: unique pattern and potential mechanisms. J Pain Symptom Manage. 1990;5:262-264.
66.
Grever MR, Leiby JM, Kraut EH, et al. Low dose deoxycoformycin in lymphoid malignancy. J Clin Oncol.1985;3:1196-1201.
67.
Grem JK, King SA, Chun HG, et al. Cardiac complications observed in elderly patients following 2'deoxycoformycin therapy. Am J Hematol. 1991 ;38: 245-247.
68.
Grever MR, Malspeis L., Kraut EH, et al. Combination of 2'-deoxycoformycin and vidarabine in advanced malignancy: clinical and biochemical observations. Cancer Treat Symp.1984;2:97-104.
69.
Plunkett W. , Benjamin RS, Keating MJ, et al. Modulation of 9-β-d-arabinofuranosyladenine 5'-triphosphate deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-β-D-arabinofuranosyladenine. Cancer Res.1982; 42:2092-2096.
70.
Gryn J., Gordon R., Bapat A., et al. Pentostatin increases the acute toxicity of high dose cyclophosphamide . Bone Marrow Transplant.1992 ;12:217-220.
71.
Hande KR, Noone RM, Stone WJSevere allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med.1984;7G:47-56.
72.
Kane BJ, Kuhn JG, Roush MKPentostatin: an adenosine deaminase inhibitor for the treatment of hairy cell leukemia. Ann Pharm.1992;26:939-947.
73.
Product information. Nipent. Parke Davis, Morris Plains, NJ, 1991.
74.
Al-Razzak LA , Benedetti AE, Waugh WN, et al. Chemical stability of pentostatin (NSC-218321): a cytotoxic and immunosuppressive agent. Pharmaceut Res.1990;7:452-460.
75.
Trissel LA, Fulton B., Tramonte SMVisual compatibility of ondansetron with chemotherapeutic agents, antibiotics, and other selected drugs during simulated Y-site injection. Presented at the 25th Annual ASHP Midyear Clinical Meetings and Exhibit, Las Vegas, NV, 1990. Abstract P-468R.
